secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123437
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029
-------------------------------------------------------------------------

- Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.
- Cash and cash equivalents at Sept. 30, 2024: $334.5M, with additional $27.6M from underwriter option in Oct. 2024.
- IPO and concurrent private placement yielded ~$189.5M net, plus $27.6M from underwriter option; cash sufficient into 2029.
- Phase 2 STRIDES trial of azelaprag + tirzepatide for obesity dosed first patient; top-line results expected Q3 2025.
- Appointed former GSK CEO Jean-Pierre Garnier as Board Chair, succeeding James Healy who remains a director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000095017024123437/0000950170-24-123437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000095017024123437/bioa-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer